Be Clinical raised ₹21 Cr to double down on clinically tested Indian skincare

Be Clinical is a D2C Indian skincare brand developing clinically tested products with dermatologically active ingredients for ageing-related concerns.

That clinically tested, dermatologically active skincare for ageing concerns — made in-house and evidence-validated — can differentiate in India's crowded BPC market

₹21 Cr (about $2.2 Mn) seed extension led by Sauce with V3 Ventures and angels; earlier ₹6 Cr seed led by V3 Ventures with Titan Capital, and ₹2 Cr from Titan Capital and Aditya Agarwal.

Hemangi Dhir founded Be Clinical and launched it in 2025 after two years of R&D, targeting ageing-related skin concerns among Indian consumers.

It claims 1.2 lakh orders since launch with a healthy share of repeat purchases, sells through its website plus Amazon and Flipkart, and raised ₹21 Cr to strengthen R&D, expand into skin, body and haircare, scale manufacturing, and enter new markets.

Clinical testing before launch is expensive but turns marketing claims into evidence, the scarcest asset in Indian skincare.

Owning manufacturing and R&D keeps the efficacy story honest — and defensible against copycats.

Ageing-related skincare among Indian consumers is an untapped demographic per its investor, away from the whitening-and-acne mainstream.

In a claims-saturated category, paying for clinical proof is a moat — if you own the testing and the manufacturing that backs it.

As of 2026-08-22 Be Clinical is deploying the ₹21 Cr into R&D, a wider skin, body and haircare portfolio, manufacturing capacity and new markets and geographies, while strengthening its clinical testing.